第六章 結論
附方 2. 喬三余方-陰陽攻積丸
不拘食積、痰積、水積、瘀積、虫積，
〔組成〕吳茱萸、炮乾薑、官桂、炒川烏、薑汁炒川連、薑半夏、浙 茯苓、炒延胡、人參各一兩，上沉香，真琥珀各五錢，巴豆霜一錢，
為末，皂角四兩煎汁糊丸，綠豆大，每服八分，加至錢半，淡薑湯下。
最有效力。
參考文獻
1. Parkin DM, Bray F, Ferlay J, Pisanil Paola. Global cancer statistics 2002. CA Cancer J Clin. 2005;55(2): 74-108.
2. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G.
Current management strategy of hepatocellular carcinoma. World J Gastroenterol. 2009;15(26): 3210-3216.
3. Livraghi T, Makisalo H, Line PD. Treatment options in
hepatocellular carcinoma today. Scand J Surg, 2011. 100(1): 22-29.
4. 行政院衛生署，98 年主要死因統計. 2010.
http://www.doh.gov.tw/CHT2006/DM/DM2_p01.aspx?class_no=2 5&level_no=1&doc_no=76013
5. El-Serag HB, Rudolph KL. Hepatocellular carcinoma:
epidemiology and molecular carcinogenesis. Gastroenterology.
2007;132(7): 2557-2576.
6. Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol. 2010;45(8): 794-807.
7. Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett. 2009; 286(1): 22-28.
8. Lei HY, Chang CP. Lectin of Concanavalin A as an anti-hepatoma therapeutic agent. J Biomed Sci. 2009;16:10.
9. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P.
Molecular bases for the development of hepatitis B virus
(HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol. 2000; 10(3): 211-231.
10. Ni YH, Huang L M, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY, Chen DS. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterol. 2007;132(4): 1287-1293.
11. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP.
Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med.
1990;150(5): 1051-1054.
12. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23(13): 2892-2899.
13. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G.
Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol.
2002;155(4): 323-331.
14. 王伯祥主編：中醫肝膽病學，中國中醫藥科技出版社，北京 1993；
pp. 170-218, 261-263, 300-323.
15. Keating GM , Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2): 223-240.
16. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10): 3129-3140.
17. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24): 11851-11858.
18. Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao ZJ.
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007;282(6):
3428-3432.
19. Landriscina M, Piscazzi A, Fabiano A, Maddalena F, Costantino E, Farese A, Bufo P, Cignarelli M. Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating
hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype. Thyroid.
2009;19(6): 629-637.
20. Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, Caparro M, Teitelbaum UR, Giantonio B, O'Dwyer PJ, Shaked A, Reddy R, Olthoff K. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Cancer. 2011;117(14):3187-3192.
21. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis:
development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009; 2: 45.
22. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M. Expression and prognostic roles of the G1-S modulators in hepatocellular
carcinoma: p27 independently predicts the recurrence. Hepatology.
1999; 30(1): 90-99.
23. Kidner T, Dai M, Adusumilli PS, Fong Y. Advances in experimental and translational research in the treatment of hepatocellular carcinoma. Surg Oncol Clin N Am.2008;17(2):
377-379, ix.
24. Comunale MA, Rodemich-Betesh L, Hafner J, Wang M, Norton P,
Di Bisceglie AM, Block T, Mehta A. Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients:
implications for a biomarker of hepatocellular carcinoma. PLoS One. 5(8): e12419.
25. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RSJr, Rafii S,Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008; 26(18):
2992-2998.
26. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Klempnauer J, Flemming P, Franco S, Blasco MA, Manns MP, Rudolph KL. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J.
2002; 16(9): 935-942.
27. Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol. 2009; 24(8): 1352-1357.
28. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children.
Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;
336(26): 1855-1859.
29. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008; 14(1): 1-14.
30. Zerhouni EA. US biomedical research: basic, translational, and clinical sciences. JAMA. 2005; 294(11): 1352-1358.
31. Brown K, Balmain A. Transgenic mice and squamous multistage skin carcinogenesis. Cancer Metastasis Rev. 1995; 14(2): 113-124.
32. Boutwell RK. Model systems for defining initiation, promotion, and progression of skin neoplasms. Prog Clin Biol Res. 1989; 298:
3-15.
33. Bickers DR, Lowy DR. Carcinogenesis: a fifty-year historical perspective. J Invest Dermatol. 1989;92(4 Suppl): 121S-131S.
34. Trosko JE. Commentary: is the concept of "tumor promotion" a useful paradigm? Mol Carcinog. 2001;30(3): 131-137.
35. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991;
1072(2-3): 129-157.
36. Hsiang CY, Wu SL, Ho TY. Activation of activator protein 1 and extracellular signal-regulated kinases in human hepatocellular transformation. Tumour Biol. 2004;25(5-6): 313-320.
37. Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene. 1998; 16(21):
2711-2721.
38. Domann FE, Levy JP, Birrer MJ, Bowden GT, Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ.
1994; 5(1): 9-16.
39. Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ, Jonat C, Herrlich P, Karin M. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell. 1987; 49(6): 729-739.
40. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH.
Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A. 1994;91(2): 609-613.
41. Alani R, Brown P, Binetruy B, Dosaka H, Rosenberg RK, Angel P, Karin M, Birrer MJ. The transactivating domain of the c-Jun
proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol. 1991;11(12): 6286-6295.
42. Huang C, Ma WY, Dong Z, Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P+ cells. Mol Cell Biol. 1996;16(11):
6427-6435.
43. Strickland PT. Photocarcinogenesis by near-ultraviolet [68]
radiation in Sencar mice. J Invest Dermatol. 1986; 87(2): 272-275.
44. Staberg B, Wulf HC, Klemp P, Poulsen T, Brodthagen H. The carcinogenic effect of UVA irradiation. J Invest Dermatol. 1983;
81(6): 517-519.
45. Dong, Z, Crawford HC, Lavrovsky V, Taub D, Watts R, Matrisian LM, Colburn NH. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol Carcinog.1997;19(3): 204-212.
46. Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA, Dong Z, Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci U S A. 1997;94(11):
5826-5830.
47. Li JJ, Dong Z, Dawson MI, Colburn NH. Inhibition of tumor promoter-induced transformation by retinoids that transrepress
AP-1 without transactivating retinoic acid response element.
Cancer Res. 1996;56(3): 483-489.
48. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P. Antitumor promotion and antiinflammation:
down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990;62(6): 1189-1204.
49. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun. 1997;236(1): 54-58.
50. Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KS, Liaw YF. Constitutive activation of nuclear factor kappaB in
hepatocellular carcinoma. Cancer. 2000;89(11): 2274-2281.
51. Aggarwal BB, Totpal K, LaPushin R, Chaturvedi MM, Pereira-Smith OM, Smith JR. Diminished responsiveness of senescent normal human fibroblasts to TNF-dependent
proliferation and interleukin production is not due to its effect on the receptors or on the activation of a nuclear factor NF-kappa B.
Exp Cell Res. 1995;218(1): 381-388.
52. Sawai H, Okazaki T, Yamamoto H, Okano H, Takeda Y, Tashima M, Sawada H, Okuma M, Ishikura H, Umehara H. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J Biol Chem. 1995;270(45): 27326-27331.
53. Huang C, Ma WY, Young MR, Colburn N, Dong Z, Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci U S A. 1998;95(1): 156-161.
54. Franklin CC, Kraft AS, Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in
U937 human leukemic cells. Oncogene. 1995;11(11): 2365-2374.
55. Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, Spiegelman BM. c-fos is required for malignant progression of skin tumors. Cell. 1995; 82(5): 721-732.
56. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ. 1996;7(3):
351-359.
57. Young MR, Li JJ, Rincon M, Flavell RA, Sathyanarayana BK, Hunziker R, Colburn N. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor
promotion. Proc Natl Acad Sci U S A. 1999; 96(17): 9827-9832.
58. Chen N, Nomura M, She QB, Ma WY, Bode AM, Wang L, Flavell RA, Dong Z. Suppression of skin tumorigenesis in c-Jun
NH(2)-terminal kinase-2-deficient mice. Cancer Res. 2001;61(10):
3908-3912.
59. Liu G,Bode A, Ma WY, Sang S, Ho CT, Dong Z. Two novel
glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line. Cancer Res., 2001. 61(15): p. 5749-5756.
60. Cheng WY, Hsiang CY, Bau DT, Chen JC, Shen WS, Li CC, Lo HY, Wu SL, Chiang SY, Ho TY. Microarray analysis of
vanillin-regulated gene expression profile in human
hepatocarcinoma cells. Pharmacol Res. 2007; 56(6): 474-482.
61. Hsiang CY, Lai IL, Chao DC, Ho TY. Differential regulation of activator protein 1 activity by glycyrrhizin. Life Sci. 2002;70(14):
1643-1656.
62. Lamb RF, Hennigan RF, Turnbull K, Katsanakis KD, MacKenzie ED, Birnie GD, Ozanne BW. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol. 1997;17(2): 963-976.
63. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem. 1996;271(23): 13422-13429.
64. Arsura M, Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 2005;229(2): 157-169.
65. Sato Y, Kato J, Takimoto R, Takada K, Kawano Y, Miyanishi K, Kobune M, Takayama T, Matunaga T, Y Niitsu. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut. 2006;
55(12): 1801-1808.
66. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene. 2001; 20(19): 2401-2412.
67. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog. 2006;45(6): 355-361.
68. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, Bernuau D. Activation of NF-kappa B, AP-1 and STAT
transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol. 2002;37(1): 63-71.
69. Eisen-Vandervelde AL, Waggoner SN, Yao ZQ, Cale EM, Hahn CS, Hahn YS. Hepatitis C virus core selectively suppresses
interleukin-12 synthesis in human macrophages by interfering with AP-1 activation. J Biol Chem. 2004; 279(42): 43479-43486.
70. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ,
Kagnoff MF, Karin M. IKKbeta links inflammation and
tumorigenesis in a mouse model of colitis-associated cancer. Cell.
2004;118(3): 285-296.
71. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y.
NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 2004;431(7007): 461-466.
72. 元．朱震亨：丹溪治法心要，人民衛生出版社, 2001；pp. 586.
73. 沈祥春、張貴林、任光友：左金丸總生物鹼對胃腸功能的影響。
中藥藥理與臨床 2006；06: 34-36.
74. 國家藥典委員會編：中華人民共和國藥典，化學工業出版社，
北京2005;1: pp. 412-413.
75. 龔艷青、文彬：左金丸對大腸癌 APC 表達及 DNA 甲基轉移酶 活性的影響。南昌大學學報(醫學版) 2010;(12): 46-49.
76. 孫麗群、胡運蓮、譚大琦、薑楠：加味左金丸治療大鼠慢性萎 縮性胃炎癌前病變的病理研究。湖北中醫雜志 2005;(03): 11-13.
77. 文彬、熊旻利、戴偉怡、梁齊桁、劉玲、陳蔚文：左金丸及反 左金丸對實驗性大腸癌不同時期甲基轉移酶表達的影響。世界 華人消化雜誌 2009;(20): 2074-2078.
78. 文彬、黃秋淩、龔艷青、陳蔚文：左金丸及其主要單體成分對 大腸癌的干預作用。世界華人消化雜誌 2009;(19): 1936-1941.
79. Chiou WF, Liao JF, Chen CF. Comparative study of the
vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa. J Nat Prod. 1996; 59(4): 374-378.
80. Xu SB, Huang YM, Lau CN, Wat CK, Kong YC. Hypotensive effect of dehydroevodiamine from Evodiae Fructus. Am J Chin Med. 1982;10: 75-85.
81. Chiou WF, Chou CJ, Liao JF, Sham AY, Chen CF. The mechanism
of the vasodilator effect of rutaecarpine, an alkaloid isolated from Evodia rutaecarpa. Eur J Pharmacol. 1994; 257(1-2): 59-66.
82. Chen CF, Chen SM, Lin MT, Chow SY. In vivo and in vitro studies on the mechanism of cardiovascular effects of Wu-Chu-Yu
(Evodiae fructus). Am J Chin Med. 1981; 9(1): 39-47.
83. Chiou WF, Chou CJ, Shum AY, Chen CF. The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action.
Eur J Pharmacol. 1992; 215(2-3): 277-283.
84. Ogasawara M, Matsubara T, Suzuki H. Inhibitory effects of
evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biol Pharm Bull. 2001; 24(8):
917-920.
85. Wu CL, Hung CR, Chang FY, Lin LC, Pau KY, Wang PS. Effects of evodiamine on gastrointestinal motility in male rats. Eur J Pharmacol. 2002; 457(2-3): 169-176.
86. Zhang Y, Wu LJ, Tashiro S, Onodera S, Ikejima T. Evodiamine induces tumor cell death through different pathways: apoptosis and necrosis. Acta Pharmacol Sin. 2004; 25(1): 83-89.
87. Ueng YF, Wang JJ, Lin LC, Park SS, CF Chen. Induction of cytochrome P450-dependent monooxygenase in mouse liver and kidney by rutaecarpine, an alkaloid of the herbal drug Evodia rutaecarpa. Life Sci. 2001; 70(2): 207-217.
88. Ueng YF, Ko HC, Chen CF, Wang JJ, Chen KT. Modulation of drug-metabolizing enzymes by extracts of a herbal medicine Evodia rutaecarpa in C57BL/6J mice. Life Sci. 2002;71(11):
1267-1277.
89. Sheu JR, Kan YC, Hung WC, Su CH, Lin CH, Lee YM, Yen MH.
The antiplatelet activity of rutaecarpine, an alkaloid isolated from
Evodia rutaecarpa, is mediated through inhibition of phospholipase C. Thromb Res. 1998;92(2): 53-64.
90. Sheu JR, Hung WC, Lee YM, Yen MH, Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from Evodia rutaecarpa. Eur J Pharmacol. 1996;318(2-3): 469-475.
91. 吳命選、郭明欣、陳立奇、陳介甫、柯漢傑：中藥吳茱萸炮製 後之含量分析研究。臨床生藥學 1999; 99(25): 114-118.
92. 吳泰賢：以 AP-1 為標的開發肝細胞轉形藥物，中國醫藥大學醫 學研究所碩士論文，台中 2002；pp. 23, 29.
93. 宋．林億校正：黃帝內經素問，引自醫統正脈全書，新文豐出 版公司，台北1975；1：pp.87-89.
94. 宋．林億校正：黃帝內經素問，引自醫統正脈全書，新文豐出 版公司，台北1975；1：pp.70.
95. 宋．林億校正：黃帝內經素問，引自醫統正脈全書，新文豐出 版公司，台北1975；2：pp.743-744.
96. 清．石壽棠撰、王新華點注：醫原，江蘇科技出版社，江蘇 1983；
pp. 8-9.
97. 宋．林億校正：黃帝內經素問，引自醫統正脈全書，新文豐出 版公司，台北1975；pp. 381.
98. 宋．林億校正：黃帝內經素問，引自醫統正脈全書，新文豐出 版公司，台北1975；1：pp. 280, 285-286.
99. 明．陽繼洲原著、黑龍江祖國醫藥研究所校釋：針灸大成校釋，
人民衛生出版社，北京 1995；pp. 360
100. 清．唐笠山纂輯：吳醫匯講，上海科技出版社，上海 1983；pp.
40.
101. 清．姚止庵撰：素問經注節解，人民衛生出版社，北京 1963；
pp. 335.
102. 宋．林億校正：黃帝內經素問，引自醫統正脈全書，新文豐出 版公司，台北1975； pp. 757-758.
103. 明．張介賓：類經，中國中醫藥出版社．北京 1997；pp. 381 104. 清．吳達著：醫學求是，江蘇科學技術出版社，江蘇 1984；pp.
13.
105. 清．趙晴初著：廣輯存存齋醫話稿，引自近代中醫珍本集，浙 江科學技術出版社，杭州1994；pp. 179.
106 清．張景燾：馤塘醫話，引自中國醫學大成，上海科學技術出 版社，上海 1990；39：15-16
107. 清．黃元御著：四聖心源，引自黃元御醫學全書，中國中醫藥 出版社，北京 1999；pp. 789-790
108. 彭子益．李可主校：圓運動的古中醫學，中國中醫藥出版社，
北京 2007；pp. 11.
109. 元．滑壽：難經本義，引自醫統正脈全書, 新文豐出版公司, 台 北1975； 5: pp. 3125.
110. 元．滑壽：難經本義，引自醫統正脈全書, 新文豐出版公司, 台 北1975； 5: pp. 3116.
111. 清．何夢瑤輯：醫碥，上海科學技術出版社，蘇州，1982；pp.
113-115.
112. 宋．東軒居士增注，衛濟寶書，引自文淵閣四庫全書電子版，
迪志文化出版公司，香港2002；pp. 1-41.
113. 南宋．楊士瀛撰、明．朱崇正附遺，仁齋直指外四種，上海古 籍出版社，上海 1991；pp. 423-466
114. 明．李時珍：本草綱目，中國醫藥研究所，台北 1988；3：pp.
145-147
115. 清．吳儀洛：成方切用，上海科學技術出版社，上海 1958；4：
pp. 152
116. 漢．張仲景著：金匱要略，引自醫統正脈全書，新文豐出版公 司，台北1975；5：pp. 3352
117. 清．陳士鐸：辨證錄，人民衛生出版社，北京 1989；13:pp. 100, 267, 442, 769-770.
118. 清．張秉成：成方便讀，啟業出版社 , 台北 1981；pp.104.
118. 清．張秉成：成方便讀，啟業出版社 , 台北 1981；pp.104.